Metabolon Meta IMD Test
Metabolon has launched Meta IMD through its CLIA laboratory-developed test. The test identifies hundreds of metabolites associated with a wide range of inherited metabolic disorders — including developmental delay, seizures, low blood sugar, or speech and/or language delay — from a small plasma sample. A 250 microliter plasma sample provides specific information to assist the physician in deciding what additional clinical tests are needed to confirm or clarify a diagnosis, the company said. Results are typically delivered in about 21 days.